Point Therapeutics to Present at Adams Harkness 25th Annual Summer Seminar
August 02 2005 - 8:46AM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced that Don Kiepert,
President and CEO, will present at the Adams Harkness 25th Annual
Summer Seminar on Wednesday, August 3, 2005 at 1:30 p.m. ET at the
Boston Marriot Long Wharf Hotel. Mr. Kiepert will review key
research and development accomplishments and discuss upcoming
corporate initiatives. A live Web cast of the presentation will be
available on the Company's Web site, www.pther.com at 1:30 p.m. ET,
August 3, 2005. About Point Therapeutics, Inc.: Point is a
Boston-based biopharmaceutical company developing a family of
dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2
diabetes and as vaccine adjuvants. Its lead product candidate,
talabostat (PT-100), is a small molecule drug in Phase 2 clinical
trials. Talabostat is orally-active and, through a novel mechanism
of action, has the potential to inhibit the growth of malignant
tumors and to support the reconstitution of the hematopoietic
system. In 2004, Point initiated four Phase 2 clinical trials of
talabostat. The trials are studying talabostat in combination with
docetaxel in metastatic non-small cell lung cancer, talabostat as a
single agent in metastatic melanoma, talabostat in combination with
cisplatin in metastatic melanoma, and talabostat in combination
with rituximab in advanced chronic lymphocytic leukemia. In June of
2005, Point announced the initiation of a fifth Phase 2 clinical
trial studying talabostat in combination with gemcitabine in
metastatic pancreatic cancer. In addition, Point's portfolio
includes two other DPP inhibitors in preclinical
development--PT-630 for type 2 diabetes, and PT-510 as a vaccine
adjuvant. Certain statements contained herein are not strictly
historical and are "forward looking" statements as defined in the
Private Securities Litigation Reform Act of 1995. This information
includes statements on the prospects for our drug development
activities and results of operations based on our current
expectations, such as statements regarding certain milestones with
respect to our clinical program and our product candidates.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "expects," "may,"
"will," "should," "seeks," "plans," "schedule to," "anticipates" or
"intends" or the negative of those terms, or other variations of
those terms of comparable language, or by discussions of strategy
or intentions. A number of important factors could cause actual
results to differ materially from those projected or suggested in
the forward looking statement, including, but not limited to, the
ability of Point to (i) successfully develop and manufacture
products, (ii) obtain external funding to finance the operations,
(iii) obtain the necessary regulatory approvals, and (iv) obtain
and enforce intellectual property rights, as well as the risk
factors described in Point's Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on May 10, 2005 and
from time to time in Point's other reports filed with the
Securities and Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles